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Abstract
Epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) is one of the
genetic targeted medicines that is used to treat non-small-cell lung cancer. However, because
EGFR-TKIs have a specific target, they are not believed to benefit all non-small-cell cancer
patients.
We conducted a meta-analysis synthesizing 9 randomized controlled trials (RCTs) to
systematically evaluate the effectiveness of EFGR-TKIs among two patient populations:
unselected patients with unknown EGFR mutation status and selected patients harboring EGFR
mutation
Among unselected patients, the efficacy of EGFR-TKIs is inferior to chemotherapy. The
hazard of disease progression in the EGFR-TKI group is 1.46 times that in the chemotherapy group
(95% CI (1.29, 1.65)). This result is consistent in the subgroups of male, smoker, and patients with
all subtypes of non-small-cell lung cancer. However, there is no significant difference of hazard
of disease progression among subgroups of female and non-smoker.
Among EGFR mutant patients, the efficacy of EGFR-TKIs is superior to chemotherapy.
Random effects model estimated the hazard of progression in the EGFR-TKI group to be 0.33
times that in the chemotherapy group (95% CI (0.24, 0.46)). Fixed effect model estimates the
hazard of progression in the EGFR-TKIs group to be 0.32 times that in the chemotherapy group
(95% CI (0.27, 0.38)).This result is consistent in the subgroups of current smoker, non-smoker,
male and female. There is no significant difference of hazard of disease progression among
subgroup of past smoker (𝑃𝑜𝑜𝑙𝑒𝑑 𝐻𝑅 = 0.83 𝑤𝑖𝑡ℎ 𝑎 95% 𝐶𝐼 (0.36, 1.92)).
Although EGFR-TKIs have provided an alternate solution for advanced non-small-cell
patients, it cannot benefit all patients. Among patients not harboring EGFR mutation, it could be
more hazardous than chemotherapy. Among Patients harboring EGFR mutation, it has shown
significantly better efficacy than chemotherapy. However, the efficacy of EGFR-TKIs vary
considerably among patients who had history of smoking. There is evidence that even among
EGFR mutant patients, smoking could hinder the efficacy of EGFR-TKIs. The hazard of disease
progression of past smokers is even greater than that of current smokers. More research needs to
be done to further explore the pathological relationship between smoking and EGFR-TKI efficacy.
iii

Acknowledgements
I would like to express my deepest gratitude to my thesis advisor: Professor Maria M.
Ciarleglio, for the insights, advices, and guidance she has provided in the creation of this thesis. I
am forever grateful for the support and help she has given to me during my journey at the Yale
School of Public Health.
In addition, I have been very fortunate to have worked with Professor Xinhan Zhao in
completion of this thesis. His expertise, brilliance, and passion for cancer research truly have
influenced me in many ways.
I want to thank all of my families and friends, who always inspire, energize, and embolden
me.
Finally, I want to thank my mom and dad for the love they have provided through my entire
life.

iv

Table of Contents
Abstract ................................................................................................................................................ iii
Acknowledgements ............................................................................................................................... iv
List of Figures ....................................................................................................................................... vi
List of Tables ....................................................................................................................................... vii
1. Introduction ....................................................................................................................................... 1
1.1 Overview of Lung Cancer: Public Health Significance ................................................................... 1
1.2 Treatment Strategies and Latest Progress ....................................................................................... 2
1.3 Motivation Behind this Thesis ........................................................................................................ 4
2. Methods.............................................................................................................................................. 4
2.1 Study Identification and Selection .................................................................................................. 5
2.1.1 Criteria for Inclusion and Selection ......................................................................................... 5
2.1.2 Literature Search Strategy ....................................................................................................... 5
2.2 Assessment of Risk of Bias Criteria ............................................................................................... 6
2.3 Data Extraction .............................................................................................................................. 8
2.4 Measuring the Treatment Effect ..................................................................................................... 8
2.5 Statistical Analysis ......................................................................................................................... 8
2.5.1 Computing .............................................................................................................................. 6
2.5.2 Assessment of Heterogeneity .................................................................................................. 8
2.5.3 Assessment of Publication Bias ............................................................................................... 8
2.5.4 Subgroup Analyses ................................................................................................................. 9
3. Results ................................................................................................................................................ 9
3.1 Description of the Studies Included ................................................................................................ 9
3.2 Assessing Risk of Bias ................................................................................................................. 11
3.3 Primary Outcomes ....................................................................................................................... 13
3.3.1 The efficacy of EGFR-TKIs among unselected patients ......................................................... 13
3.3.2 The efficacy of EGFR-TKIs among patients harboring EGFR mutation ................................. 18
4. Conclusion and Discussion .............................................................................................................. 22
5. The Future of Cancer Treatment .................................................................................................... 24
List of References ................................................................................................................................ 25
Appendix R-Code ................................................................................................................................ 27

v

List of Figures
Figure 1 Study Selection Flow Diagram ................................................................................................ - 6 Figure 2 Risk of Bias Graph ................................................................................................................ - 12 Figure 3 Risk of Bias Summary ........................................................................................................... - 12 Figure 4 Forest Plot of Hazard Ratios among Unselected Patients ...................................................... - 13 Figure 5 Funnel Plot of Asymmetry I .................................................................................................. - 14 Figure 6 Forest Plot of Hazard Ratios among Unselected Male Patients ............................................. - 15 Figure 7 Forest Plot of Hazard Ratios among Unselected Female Patients .......................................... - 15 Figure 8 Forest Plot of Hazard Ratios among Unselected Smoker ....................................................... - 16 Figure 9 Forest Plot of Hazard Ratios among Unselected Non-smoker ............................................... - 16 Figure 10 Forest Plot of Hazard Ratios among Unselected Patients with adenocarcinoma ................. - 17 Figure 11 Forest Plot of Hazard Ratios among Unselected Patients with Other Types of NSCLC .......... - 17 Figure 12 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients ................................... - 18 Figure 13 Funnel Plot of Asymmetry II ............................................................................................... - 19 Figure 14 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Past Smoker - 20 Figure 15 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Current Smoker .. 20 Figure 16 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Non-smoker - 21 Figure 17 Forest Plot of Hazard Ratios among Selected EGFR Mutant Male Patients ......................... - 22 -

vi

List of Tables
Table 1 EPOC Risk of Bias Assessment Criteria ..................................................................................... - 6 Table 2 Characteristics of Included Studies ........................................................................................ - 12 -

vii

1. Introduction
1.1. Overview of Lung Cancer：Public Health Significance
Lung cancer is one of the major public health threats and leading causes of death all over
the world. In 2012, lung cancer was the most common cancer worldwide, with 1.82 million new
cases of lung cancer comprising 13% of all new cancer diagnoses. (1) The mortality-to-incidence
rate ratio, which serves as an indirect measure of cancer survival, of lung cancer is 0.87. (2) The
high incidence coupled with the high fatality of this disease has made lung cancer the most
common cause of cancer death in the world, responsible for approximately 20% of all cancer
deaths. (1) Due to constrained medical resources and limited treatment options, lung cancer poses
an even more severe public health problem to developing countries, such as China. The incidence
rate of lung cancer in China has been rising rapidly in recent years. For example, in Beijing, the
incidence rate has increased 38.8% from 39.30 cases per 100,000 population to 54.55 cases per
100,000 population from 1998 to 2007. (3) It is anticipated that by 2025, there will be more than
1 million individuals diagnosed with lung cancer in China. This will make China the country with
most lung cancer cases in the world. (4)
Many risk factors are proven to be associated with lung cancer, such as air pollution and
cigarette smoking. (4) Air pollution has undoubtedly intensified the public health burden of lung
cancer in China as byproducts of China’s relentless socioeconomic development in the past
decades. With the rapid industrialization process, the air quality continues to deteriorate in China.
Many cities in China are often shrouded with a blanket of toxic smog with high concentration of
fine particulate matter (PM 2.5), which is considered to be one of the most detrimental particles to
health. According to the U.S. Embassy’s air quality monitor in Beijing, the PM 2.5 concentration
on 12/21/2015 reached a very unhealthy level of 156 micrograms per cubic meter that could cause
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severe respiratory effects and lung diseases, with the World Health Organization’s maximum
recommendation limit of 25 micrograms per cubic meter. (5)
Furthermore, China remains the largest consumer of cigarettes in the world with 350
million smokers and 740 million passive smokers. (6) Each year, China process about 2.66 million
tons of tobacco leaves, which approximately equals one-third of world’s total tobacco leaf
production. (6) If the Chinese government does not effectively control air pollution and regulate
cigarette sales, there is no doubt that incidence rate of lung cancer will further increase in the future.
1.2. Treatment Strategies and Latest Progress
There are two types of lung cancer based on the morphological differences of the lung
tumor, namely small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Nonsmall-cell lung cancer approximately accounts for 80-85% of all lung cancers. (7) At the time of
diagnosis with non-small-cell lung cancer, more than 30% of patients are at the late stage of the
disease. (7) Due to the limited methods of treatment, the 5-year survival rate of non-small-cell lung
cancer patients are often less than 15%. (7) As a consequence, the treatment strategy of non-smallcell lung cancer has become one of the most active clinical research areas.
Differentiated by starting lung cells, non-small-cell lung cancer is further divided into three
main subcategories, adenocarcinoma, squamous cell (epidermoid) carcinoma and large cell
(undifferentiated) carcinoma. Other types of non-small-cell lung cancer, including adenosquamous
carcinoma and sarcomatoid carcinoma are very rare. (7) However, the treatment and prognosis of
all types of non-small-cell lung cancers are often very similar.
Depending on the stage of the lung cancer and patient characteristics, multiple treatment
options are available for non-small-cell lung cancer patients, including surgery, chemotherapy,
radiotherapy, immunotherapy, radiofrequency ablation and targeted therapy. Among all of the
-2-

options, surgery is the first choice for those patients in early stage of non-small-cell lung cancer
because it has the highest possibility of cure. However, for those patients diagnosed at advanced
stage who cannot benefit from surgery, the efficacy of traditional radiotherapy and chemotherapy
are often unsatisfactory due to a lack of specificity and severe adverse effects.
In recent years, molecular targeted therapy toward the tumor signaling transduction
pathways has gradually become the focus of non-small-cell lung cancer treatment research. After
a long period of plateau, scientists have made breakthroughs in the research and application of
molecular targeted therapy.
With the development of molecular biology, scientists have a much more clear
understanding of tumor signaling transduction pathways, and have identified more and more lung
cancer molecular targets, including EGFR mutation, BRAF mutation, KRAS mutation, ALK
mutation, and ROS1 fusion. Targeted medicines based on these gene mutations has inaugurated a
new era for non-small-cell lung cancer treatment and offered hope for patients with advanced stage
non-small-cell lung cancer. Compared with traditional chemotherapy and radiotherapy, targeted
therapy could greatly reduce the recurrence rate and prevent metastasis of the tumor without
eliciting severe adverse effects for some patients.
There are mainly three types of targeted medicine based on different transduction pathways
in non-small-cell lung cancer treatment, namely, epidermal growth factor receptor – tyrosine
kinase inhibitors, angiogenesis inhibitors and multi targeted antiangiogenic tyrosine kinase
inhibitors. Among all signaling transduction pathways, epidermal growth factor receptor is the one
with the most well-developed research and proven evidence of efficacy. Epidermal growth factor
receptor - tyrosine kinase inhibitors, such as erlotinib, gefitinib, and afatinib have become the
standard first line treatment for advanced stage non-small-cell lung cancer patients.
-3-

Because EGFR-TKIs have a specific target, they are not believed to benefit all non-smallcell lung cancer patients. Some research has shown that Asian, non-smoker and females have a
relatively higher response rate of EGFR-TKIs. Other research has shown that the response rate
among patients with EGFR mutation could reach 50% to 80%. The response rate among patients
without EGFR mutation is only 10%-15%. (8, 9)
1.3. Motivation Behind this Thesis
Although there are multiple researches trying to explore the efficacy of EGFR-TKIs in
treatment of none-small-cell lung cancer. They are, to certain degree, subject to bias and might not
be representative. There has not been a high quality meta-analysis that systematically synthesized
those single studies to establish a pooled estimate both in population and representative subgroups.
Through this study, we try to provide clinicians with reliable evidence in treatment of non-smallcell lung cancer by systematically reviewing a variety of high-quality, representative randomized
clinical trials.
2. Methods
In this study, we conducted a meta-analysis synthesizing 9 randomized controlled clinical
trials to systematically compare the effectiveness of EFGR-TKIs (Gefitinib, Erlotinib, Afatinib)
and chemotherapy in treatment of non-small cell lung cancer among two patient populations:
unselected patients with unknown EGFR mutation status and selected patients harboring EGFR
mutation. The study therefore has two primary objectives:
1) Explore the efficacy of EGFR-TKIs compared with chemotherapy among unselected
patients;
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2) Explore the efficacy of EGFR-TKIs compared with chemotherapy among EGFR mutant
patients.
2.1. Study Identification and Selection
2.1.1. Criteria for Inclusion and Selection
Randomized controlled trials that included treatment arms receiving EGFR-TKIs and
treatment arms receiving chemotherapy were considered for inclusion in this systematic review.
Non-randomized studies were not eligible for inclusion. Prior to enrolling in the trials patients
must be naïve to chemotherapy but could have had resection before. All studies must have included
patients that were followed for at least 12 months and reported progression free survival. The
primary endpoint of interest is progression free survival because it is a clinically-relevant shorterterm endpoint that is less likely to be affected by subsequent therapies.
2.1.2. Literature Search Strategy
We searched Pubmed, Cochrane Library and EMBASE with the following key words:
EGFR, EGFR-TKIs, epidermal growth factor receptor, gefitinib, erlotinib, afatinib, NSCLC, nonsmall-cell lung cancer, adenocarcinoma, large cell lung cancer, squamous cell carcinoma,
adenosquamous carcinoma, sarcomatoid carcinoma. We firstly keep records of papers based on
whether the title is relevant. We then browsed the abstract of each paper to decide whether it is
qualified for further review. Non-relevant studies were then excluded. The following information
were also recorded: title, author, year of publication, journal name, patient characteristics,
interventions and outcome variables. We initially identified a total of 127 papers. First screening
excluded 97 of those. Reason for exclusion includes non-relevant topics, outdated research,
duplication and observational/retrospective study. After reading the abstract of the remaining 30
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papers, we then excluded 15 more studies. Among excluded studies, 9 enrolled patients who were
not naïve to chemotherapy and 6 studies did not contain our interested treatment arms or endpoints.
We then carefully read the full text of the remaining 15 studies. Among those, 6 were excluded
because they are not randomized controlled trials. Finally, a total of 9 randomized clinical trials
were retained. Figure 1 shows a flow chart of the literature selection process.
Figure 1 Study Selection Flow Diagram

2.2. Assessment of Risk of Bias Criteria
Risk of bias was assessed for each study using Effective Practice and Organization of Care
(EPOC) criteria. Table 1 describes the nine domains that were evaluated for each study to
determine bias. These domains evaluate potential biases including selection bias, performance bias,
detection bias, attrition bias, and reporting bias. Each study was rated as having low risk, high risk
or unclear risk of bias for each domain. Low risk of bias indicates that the bias is unlikely to affect
results. High Risk of bias indicates that bias could have affected results. Unclear risk of bias
-6-

indicates that the assessment of bias could not be adequately made or that some doubts exist about
the results. The risk of bias summary and risk of bias graph were generated by RevMan 5.3.
Table 1 EPOC Risk of Bias Assessment Criteria

Risk of Bias Domain
Low Risk of Bias
Was the allocation sequence A random component in the
adequately generated?
sequence generation process
is described
Was the allocation adequately The unit of allocation was by
concealed?
institution,
team
or
professional and allocation
was performed on all units at
the start of the study

Were
baseline
outcome
measurements similar?

Were baseline characteristics
similar?

Were incomplete outcome
data adequately addressed?
Was knowledge of the
allocated
interventions
adequately prevented during
the study?
Was the study adequately
protected
against
contamination?

Was the study free from
selective outcome reporting?
Was the study free from other
risks of bias?

High Risk of Bias
A nonrandom method is used

The unit of allocation was by
patient or episode of care and
there was some form of
centralized
randomization
scheme, an on-site computer
system or sealed opaque
envelopes were used
Performance
or
patient Important differences were
outcomes were measured present and not adjusted for in
prior to the intervention, and analysis
no important differences were
present across study groups
Baseline characteristics of the There is no report of
study and control providers characteristics in text or tables
are reported and similar
or if there are differences
between
control
and
intervention providers
Missing outcome measures Missing outcome data was
were unlikely to bias the likely to bias the results
results
Authors state explicitly that Outcomes were not assessed
the primary outcome variables blindly
were assessed blindly, or the
outcomes are objective
Allocation
was
by It is likely that the control
community, institution or group
received
the
practice and it is unlikely that intervention
the control group received the
intervention
There is no evidence that Some important outcomes are
outcomes were selectively subsequently omitted from the
reported
results
No evidence of other risk of
biases
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2.3. Data Extraction
The following variables from each RCT were recorded: specific EGFR-TKI medicine, dose,
chemotherapy plan, number of patients in both experimental group and controlled group, time of
the study, region and patient characteristics including gender, age, and stage of the cancer.
Information contained in survival curves and hazard ratios were recorded.
2.4. Measuring the Treatment Effect
Hazard ratio and its 95% CI of progression free survival was recorded. We converted these
into log scale. The standard error of log hazard ratio was computed using the following formula:
𝑆𝑒(𝑙𝑜𝑔𝐻𝑅) =

log HR−log(lower bond of 95% 𝐶𝐼)
1.96

2.5. Statistical Analysis
2.5.1. Computing
Statistical analyses were conducted using the “meta” package in the R statistical software
program.
2.5.2. Assessment of Heterogeneity
Cochran’s Q test was used to evaluate the heterogeneity between each single study. The I 2
statistic and the chi-square test were used to determine if significant heterogeneity was present.
An I2 larger than 75% and a p-value < 0.05 indicated high heterogeneity and a random effects
model should be used. Otherwise, fixed effect model would be sufficient. In addition, we reported
the estimates from both random effects model and fixed effect model. The pooled estimates were
presented by forest plots.
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2.5.3. Assessment of Publication Bias
Linear regression test of funnel plot asymmetry (Egger’s test) was used to examine
publication bias.
2.5.4. Subgroup Analyses
For the unselected patients, we performed subgroup analyses based on smoking status,
gender and cancer type. For the EGFR mutant patients, we performed subgroup analyses based on
smoking status and gender.
3. Results
3.1. Description of the Studies Included
We included a total of 9 randomized clinical trials published between 2008 and 2014, all
in English. (10-18). All trials have two treatment arms, EGFR-TKIs and chemotherapy. Four trials
were conducted in Asia (2 in China, 2 in Japan). Four trials were conducted in Europe (2 in Italy,
1 in Spain, 1 in France). One trial was conducted in the U.S. As a result, the samples are
representative geographically. Although we wanted to understand the efficacy of EGFR-TKIs
among African patients, we failed to find any randomized trial in Africa. We did not observe
significant difference between median ages of patients in each study (58-71). We observed some
imbalances between sample sizes, ranging from 103 to 973. Five studies enrolled only patients
harboring EGFR mutation (Maemodo 2010, Zhou 2011, Wu 2014, Rosell 2012 and Miisudomi
2010). The remaining four trials enrolled unselected patients. In terms of treatment plan, four of
the RCTs used Erlotinib as first line EGFR-TKIs treatment, four trials used Gefitinib as first line
EGFR-TKIs treatment and one trial used Afatinib as first line EGFR-TKIs treatment.
Chemotherapy treatment included Cisplatin, Gemcitabine, Paclitaxel, and Vinorelbine. All
-9-

patients enrolled in these studies were either in stage IIIB or IV. Most of the patients had
adenocarcinoma or squamous cell carcinoma. A small portion of them had large cell cancer and
adenosquamous carcinoma. All of the studies reported progression free survival statistics and the
hazard ratios. Overall, these studies included patients with a variety of demographical and clinical
characteristics and are therefore considered to be representative. Table 2 shows the detailed
information by treatment arm of each study included in this review.
Table 2 Characteristics of Included Studies

Study

Gridelli
2012

Group

Treatment Plan

EGFR

Erlotinib 150 mg/d

Chemo

EGFR

Cisplatin 80 mg/m2
Gemcitabine
1200
mg/m2
Gefitinib 250 mg/d

Gender
(M/F)

Median
Age

Stage

Classification

252/128

63

46 IIIB
334 IV
37 IIIB
343 IV

170 SCC+ LCC
210 AC + Other
170 SCC+ LCC
210 AC + Other

252/128

62

42/72

63.9

15 IIIB
88 IV

41/73

62.6

21ⅢB
84 Ⅳ

34/48

57

29/43

59

11 IIIB
71 IV
5 IIIB
67 IV

58

16 IIIB
226 IV

N/A

87/155
39/83

58

6 IIIB
116 IV

N/A

75/22

74

73/26

74

IIIB or
IV
(detailed
number
not
reported)

23/29

N/A

Maemodo
2010
Chemo

EGFR
Zhou
2011

Chemo

EGFR

Paclitaxel 200 mg/ m2
Carboplatin AUC 6

Erlotinib 150 mg/d
Gemcitabine 1000 mg/
m2
Carboplatin AUC 5
Afatinib 40 mg/d

Wu
2014
Chemo

EGFR

Gemcitabine 1000 mg/
m2
Cisplatin 75 mg/ m2
Gefitinib 250mg/d

Crino 2008
Chemo

EGFR

Vinorelbine Tartrate
30mg/ m2

Erlotinib 150 mg/d

7 IIB
45 IV

103 AC
1 LCC
2 ACC
3 SCC
5 Other
110 AC
0 LCC
1 ACC
2 SCC
1 Other
72 AC
10 Other
62 AC
10 Other

47 SCC
34 AC
14 LCC
2 Other
44 SCC
45 AC
7 LCC
3 Other
26 AC
26 Other
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Lilenbaum
2008

Chemo
EGFR

Carboplatin Auc 5
Taxol 200 mg/ m2
Gefitinib 250mg/d

7 IIB
44 IV
7 IIB
36 IV

32 AC
19 Other
13 SCC
22 AC
8 Other

10 IIB
32 IV

13 SCC
21 AC
8 Other
9 SCC
19 AC
14 Other
82 AC
3 LCC
1 SCC

28/23

N/A

38/5

70

34/8

71

33/9

71

6 IIB
36 IV

28/58

65

6 IIB
78 IV

19/68

65

27/59

26/60

Morère 2010
Chemo I

Gemcitabine
1250 mg/ m2

Chemo
II

Taxotere
75 mg/ m2

EGFR

Erlotinib 150 mg/d

Chemo
Rosell
2012

EGFR

1.
Cisplatin 75 mg/ m2 +
Docetaxel 75 mg/ m2
or Gemcitabine 1250
mg/ m2
2.
Carboplatin AUC 6
Docetaxel 75 mg/ m2
3.
Carboplatin AUC 5
Gemcitabine 1000 mg/
m2
Gefitinib 250 mg/d

5 IIB
82 IV

80 AC
1 LCC
6 Other

64

10 IIB
41 IV

64

9 IIB
41 IV

224 AC
58 LCC
239 SCC
65 OTER
221 AC
52 LCC
243 SCC
70 OTER

Mitsudomi
2010
Chemo

Docetaxel 60 mg/ m2
Cisplatin 780 mg/ m2

AC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large cell carcinoma; ACC: adenosquamous carcinoma; PFS: progression free survival

3.2. Assessing Risk of Bias
We carefully reviewed each entry in the Effective Practice and Organization of Care
(EPOC) criteria to evaluate the potential sources of bias. Overall, the quality of these studies was
found to be good. All of these studies have properly randomized patients to treatment arms and
reported the procedure. Furthermore, there were no severe problems in allocation concealment,
incomplete data and selective reporting. Most of the studies properly balanced the baseline
characteristics of patients. However, most of the studies we included either did not report the
- 11 -

blinding information or were not blinded among clinicians and patients. That might be a potential
source of bias. Figure 2 and figure 3 visualized the risk of bias information.

Figure 2 Risk of Bias Graph

Figure 3 Risk of Bias Summary

- 12 -

3.3. Primary Outcomes
3.3.1. The Efficacy of EGFR-TKIs among Unselected Patients
In this section, we included a total of 4 randomized clinical trials. From table 1, the studies
described in Gridelli 2012, Crino 2008, Lilenbaum 2008, Morère 2010 were included in this
analysis. Morère 2010 had two controlled chemotherapy treatment groups (Gemcitabine 1250
mg/m2 and taxotere 75 mg/ m2) so we divided it into two separate studies for the purpose of analysis.
Rosell 2012 had three chemotherapy treatment plans for the chemotherapy group. However they
analyzed those three groups as an integrated chemotherapy group and only reported one hazard
ratio. All studies reported progression free survival statistics and we pooled the hazard ratios of
these studies. The forest plot shown in Figure 4 reports the detailed results.
Figure 4 Forest Plot of Hazard Ratios among Unselected Patients

The amount of heterogeneity in the true hazard ratio is estimated to be

2

= 0. The 𝐼 2 =

0%, suggesting minimal heterogeneity. In addition, Cochran’s Q test of heterogeneity suggests
that no statistically significant heterogeneity is present with p-value = 0.756. Therefore a fixed
effect model would be sufficient. We reported the estimates from both random effects model and
fixed effect model. Both models give same results and suggest that among unselected patients, the
progression free survival in EGFR-TKIs group is worse than that in chemotherapy group.
- 13 -

Specifically, the hazard of progression in the EGFR-TKI group is 1.46 times that in the
chemotherapy group (pooled HR =1.46 with a 95% CI (1.29, 1.65)). Based on linear regression
test of funnel plot asymmetry shown in Figure 5 (Egger’s test), we fail to find evidence of
asymmetry (t = -1.2448, df = 3, p-value = 0.3016) suggesting publication bias is not a concern.
Figure 5 Funnel Plot of Asymmetry I

Two studies (Gridelli 2012 and Lilenbaum 2008) also reported hazard ratios based on
stratified analysis of smoking status, gender, and cancer type. We then also conducted subgroup
analyses based on these stratifications. The result is consistent among subgroups of male, smokers,
and patients with adenocarcinoma and other types of cancer. However, among females and nonsmokers, we did not observe significant difference of hazard of disease progression between
EGFR-TKIs group and chemotherapy group.
The hazard of disease progression among male patients who received EGFR-TKIs is
significantly greater than that of male patients who received chemotherapy. Fixed effect model
estimates the hazard of progression in the EGFR-TKI group to be 1.99 times that in the
chemotherapy group (pooled HR = 1.99 with a 95% CI (1.48, 2.66)). Random effects model
estimates the hazard of progression in the EGFR-TKI group to be 2.10 times that in the
- 14 -

chemotherapy group (pooled HR = 2.10 with a 95% CI (1.35, 3.26)). (Figure 6). We did not
observe significant difference of hazard of disease progression among female patients who
received EGFR-TKIs or chemotherapy. Both fixed effect model and random effects model
estimates the hazard of progression in the EGFR-TKI group to be 1.15 times that in the
chemotherapy group (pooled HR = 1.15 with a 95% CI (0.91, 1.46)). (Figure 7).
Figure 6 Forest Plot of Hazard Ratios among Unselected Male Patients

Figure 7 Forest Plot of Hazard Ratios among Unselected Female Patients

The hazard of disease progression among smokers who received EGFR-TKIs is
significantly greater than that of smokers who received chemotherapy. Fixed effect model
estimates the hazard of progression in the EGFR-TKI group to be 1.87 times that in the
chemotherapy group (pooled HR = 1.87 with a 95% CI (1.59, 2.20)). Random effects model
estimates the hazard of progression in the EGFR-TKI group to be 2.10 times that in the
chemotherapy group (pooled HR = 2.05 with a 95% CI (1.37, 3.08)). (Figure 8).
- 15 -

Figure 8 Forest Plot of Hazard Ratios among Unselected Smoker

We did not observe significant difference of hazard of disease progression among nonsmoking patients who received EGFR-TKIs or chemotherapy. Both random effects and fixed
effect model estimates the hazard of progression in the EGFR-TKI group to be 0.89 times that in
the chemotherapy group (pooled HR = 0.89 with a 95% CI (0.64, 1.22)). (Figure 9).
Figure 9 Forest Plot of Hazard Ratios among Unselected Non-smoker

The hazard of disease progression among adenocarcinoma patients who received EGFRTKIs is significantly greater than that of adenocarcinoma patients who received chemotherapy.
Both fixed effect model and random effects model estimates the hazard of progression in the
EGFR-TKI group to be 1.46 times that in the chemotherapy group (pooled HR = 1.46 with a 95%
CI (1.20, 1.76)). (Figure 10).
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Figure 10 Forest Plot of Hazard Ratios among Unselected Patients with adenocarcinoma

Among patients with other types of NSCLC, the fixed effect model suggest a greater hazard
of disease progression of patients in the EGFR-TKIs group. However, random effects model
suggests that there is no significant difference of hazard of disease progression of patients in
EGFR-TKIs group and chemotherapy group. In this case, the amount of heterogeneity in the true
hazard ratio is estimated to be

2

= 1407. The 𝐼 2 = 44.7%, suggesting minimal heterogeneity. In

addition, Cochran’s Q test of heterogeneity suggests that no statistically significant heterogeneity
is present with p-value = 0.1788. As a result, fixed effect model would be sufficient. Fixed effect
model estimates the hazard of progression in the EGFR-TKI group to be 1.61 times that in the
chemotherapy group (pooled HR = 1.61 with a 95% CI (1.29, 2.02)). Random effects model
estimates the hazard of progression in the EGFR-TKI group to be 1.90 times that in the
chemotherapy group (pooled HR = 1.90 with a 95% CI (0.97, 3.70)). (Figure 11).
Figure 11 Forest Plot of Hazard Ratios among Unselected Patients with Other Types of NSCLC
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3.3.2. The Efficacy of EGFR-TKIs among Patients Harboring EGFR Mutation
Six trials reported the progression free survival statistics among patients harboring EGFR
mutation (Gridelli 2012, Maemodo 2010, Zhou 2011, Wu 2014, Rosell 2012, Mitsudomi 2010).
We pooled the hazard ratios. The forest plot below (Figure 12) shows the detailed results. The
amount of heterogeneity in the true hazard ratio is estimated to be

2

= 0.1043. The 𝐼 2 = 71.8%,

suggesting maximal heterogeneity. In addition, Cochran’s Q test of heterogeneity suggests that
statistically significant heterogeneity is present with p-value = 0.0033. Therefore a random effects
model should be used. We reported the estimates from both random effects model and fixed effect
model. Both models give similar results and suggest that among EGFR mutant patients, the
progression free survival in EGFR-TKIs group is superior to that in chemotherapy group. Random
effects model estimates the hazard of progression in the EGFR-TKI group to be 0.33 times that in
the chemotherapy group (pooled HR = 0.33 with a 95% CI (0.24, 0.46)). Fixed effect model
estimates the hazard of progression in the EGFR-TKI group to be 0.32 times that in the
chemotherapy group (pooled HR = 0.32 with a 95% CI (0.27, 0.38)). (Figure 12) Based on linear
regression test of funnel plot asymmetry (Egger’s test), we fail to find evidence of asymmetry
(t = 0.3712, df = 4, p-value = 0.7293), suggesting publication bias is not a concern. (Figure 13).
Figure 12 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients
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Figure 13 Funnel Plot of Asymmetry II

Four studies also performed stratified analyses based on smoking status and gender
(Mitsudomi 2010, Rosell 2012, Wu 2014 and Zhou 2011). In terms of smoking status, Rosell 2012
and Wu 2014 divided patients into three subgroups: current smoker, non-smoker and past smoker.
Mitsudomi 2010 and Zhou 2011 combined the past smoker and current smoker as one subgroup.
As a consequence, we pooled the hazard ratios of current smokers from all four studies. But we
only used Rosell 2012 and Wu 2014 for past smoker and current smoker analyses. The results are
consistent across male, female and patients who never smoked. Among current smokers, although
the hazard of disease progression is lower in EGFR-TKIs group, it is less significant than that in
non-smokers. An interesting fact is that, among past smokers, the hazard ratio of disease
progression between EGFR-TKIs group and chemotherapy is not significantly different from 1.
With a very large variance of hazard ratio, the efficacy of EGFR-TKIs among patients who smoked
in the past varies significantly. Many patients who had a history of smoking but quit later did not
benefit from EGFR-TKIs even though they were EGFR mutant. Both fixed effect model and
random effects model give same estimates of HR = 0.83 with 95% CI (0.36, 1.92). We were
surprised that among EGFR mutant patients, the hazard of disease progression of past smokers is
even greater than that of current smokers (HR=0.48, 95% CI = (0.25, 0.92). However, we only
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included two studies so that this result may subject to bias. More research in this area needs to be
done to further address this question.
We did not observe significant difference of hazard of disease progression among past
smokers who received EGFR-TKIs or chemotherapy. Both fixed effect model and random effects
model estimates the hazard of progression in the EGFR-TKI group to be 0.83 times that in the
chemotherapy group (pooled HR = 0.83 with a 95% CI (0.36, 1.92)). (Figure 14).
Figure 14 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Past Smoker

The hazard of disease progression among current smokers who received EGFR-TKIs is
significantly lower than that of current smokers who received chemotherapy. Both fixed effect
model and random effects model estimates the hazard of progression in the EGFR-TKI group to
be 0.48 times that in the chemotherapy group (pooled HR = 0.48 with a 95% CI (0.25, 0.92)).
(Figure 15).
Figure 15 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Current Smoker
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The hazard of disease progression among non-smokers who received EGFR-TKIs is
significantly lower than that of non-smokers who received chemotherapy. Random effects model
estimates the hazard of progression in the EGFR-TKI group to be 0.25 times that in the
chemotherapy group (pooled HR = 0.25 with a 95% CI (0.16, 0.40)). Fixed effect model estimates
the hazard of progression in the EGFR-TKI group to be 0.26 times that in the chemotherapy group
(pooled HR = 0.26 with a 95% CI (0.21, 0.3)). (Figure 16).
Figure 16 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Non-smoker

The hazard of disease progression among male who received EGFR-TKIs is significantly
lower than that of male who received chemotherapy. Random effects model estimates the hazard
of progression in the EGFR-TKI group to be 0.38 times that in the chemotherapy group (pooled
HR = 0.38 with a 95% CI (0.26, 0.56)). Fixed effect model estimates the hazard of progression in
the EGFR-TKI group to be 0.38 times that in the chemotherapy group (pooled HR = 0.38 with a
95% CI (0.28, 0.53)). (Figure 17).
The hazard of disease progression among female who received EGFR-TKIs is significantly
lower than that of female who received chemotherapy. Random effects model estimates the hazard
of progression in the EGFR-TKI group to be 0.28 times that in the chemotherapy group (pooled
HR = 0.28 with a 95% CI (0.217, 0.47)). Fixed effect model estimates the hazard of progression
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in the EGFR-TKI group to be 0.30 times that in the chemotherapy group (pooled HR = 0.30 with
a 95% CI (0.23, 0.39)). (Figure 18).
Figure 17 Forest Plot of Hazard Ratios among Selected EGFR Mutant Male Patients

Figure 18 Forest Plot of Hazard Ratios among Selected EGFR Mutant Female Patients

4. Conclusion and Discussion
In this meta-analysis, we systematically evaluated the efficacy of EGFR-TKIs compared
with chemotherapy. We included 9 relatively high quality randomized controlled trials which
enrolled patients with different clinical characteristics. Statistical analysis shows that among
unselected patients (unknown EGFR mutation status), the efficacy of EGFR-TKIs is inferior to
chemotherapy. In the EGFR-TKI group, the hazard of disease progression is significantly higher
than that in chemotherapy group. However, among females and non-smokers with unknown EGFR
mutation status, we did not observe significant difference of hazard of disease progression between
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the EGFR-TKI group and the chemotherapy group. Among patients harboring EGFR mutation,
EGFR-TKIs showed superb efficacy. The hazard of disease progression in the EGFR-TKIs group
is significantly lower than that in chemotherapy group. However, patient’s smoking status can
greatly affect the efficacy. Among current smokers, although the hazard of disease progression is
lower in EGFR-TKIs group, it is less significant than that in non-smokers. Among past smokers,
the hazard ratio of disease progression between the EGFR-TKIs group and the chemotherapy
group is not significantly different from 1. The efficacy of EGFR-TKIs among patients who
smoked in the past varies significantly. Many patients who had a history of smoking but quit later
did not benefit from EGFR-TKIs even though they were EGFR mutant.
Although EGFR-TKIs have provided an alternate solution for advanced non-small-cell
patients, it cannot benefit all patients. For some patients, it might be less effective and more
hazardous than the traditional chemotherapy. EGFR mutated patients are most sensitive to EGFRTKIs and have the best prognosis. A few studies have paid attention to patient’s smoking status.
However, most of those studies classified patients to either smoker or non-smoker. In this metaanalysis, we found evidence that the efficacy of EGFR-TKIs among past smokers could be worse
than that among current smoker. However, there is no formal definition of past smoker. In Wu
2014, they define past smoker as those who smoked less than 15 pack per year and stopped more
than 1 year ago before enrolling to the trial. Rosell 2012 did not clarify the definition of past
smoker. However, this unexpected finding shed some light to future research on this topic. More
research needs to be done to further explore the pathological relationship between smoking status
and efficacy of EGFR-TKIs. Formal standard needs to be established to distinguish between
former smoker and current smoker. For example, how many cigarettes per day does a person
smoke makes him a smoker? Who should be clarified as former smoker? For how long has a person
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need to quit smoking to be considered for former smoker? Moreover, what category should passive
smoker fall in? How does the efficacy of EGFR-TKIs among passive smokers compared to
chemotherapy?
5. The Future of Cancer Treatment
The current cancer treatment is largely based on evidence-based medicine. Clinicians make
medical decisions based on macro-level characteristics such as gender, age, smoking status and
cancer type. However, even some of those are significantly associated with prognosis, they cannot
perfectly predict prognosis because they cannot differentiate the fundamental characteristics of
each patient. Two patients can have exactly same clinical characteristics but does that guarantee
their prognosis will also be same? What really differentiate each person is their unique genetic
makeup. If scientists could uncover the molecular biomarkers that drive individual variability
in clinical responses, then clinicians can then build genetic “regression model” to ensure the best
prognosis possible and even prevent cancer from happening. In the future, we look forward to
seeing the medical science come down from macro level to micro level and every patient can
receive a “personalized medicine” that is specifically designed to him/her.
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Appendix R-Code
Library(meta)
### The efficacy of EGFR-TKIs among unselected patients
> unselected = data.frame(
+ yi=c(0.4252677354,0.1739533071,0.3715635564,0.3011050928,0.4004775666),
+ vi=c(0.0792043868,0.1716695085,0.1998807468,0.230065419,0.2296272522))
> res=metagen(yi,vi,sm="HR",data=unselected)
> forest(res)
> funnel(res)
> metabias(res,method="linreg",k.min=5,plotit=TRUE)
### Unselected Male
> unselectedmale = data.frame(
+ yi=c(0.5822156199,1.057790294),
+ vi=c(0.1684611474,0.3193917743))
> res=metagen(yi,vi,sm="HR",data=unselectedmale)
> forest(res)
### Unselected Female
> unselectedfemale = data.frame(
+ yi=c(0.1570037488,0.0676586485),
+ vi=c(0.1338593186,0.2867117195))
> res=metagen(yi,vi,sm="HR",data=unselectedfemale)
> forest(res)
### Unselected Smoker
> unselectedsmoker=data.frame(
+ yi=c(0.5988365011,1.078409581),
+ vi=c(0.0852316758,0.3501874967) )
> res=metagen(yi,vi,sm="HR",data=unselectedsmoker)
> forest(res)
### Unselected Non-Smoker
> unselectednonsmoker=data.frame(
+ yi=c(-0.1165338163,-0.1625189295),
+ vi=c(0.1682414726,0.7382239709) )
> res=metagen(yi,vi,sm="HR",data=unselectednonsmoker)
> forest(res)
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### Unselected adenocarcinoma
> unselectedadenocarcinoma =data.frame(
+ yi=c(0.4054651081,0.1906203596),
+ vi=c(0.1054154333,0.2648594013))
> res=metagen(yi,vi,sm="HR",data=unselectedadenocarcinoma)
> forest(res)
### Unselected other
> unselectedother=data.frame(
+ yi=c(0.4446858213,1.238374231),
+ vi=c(0.1171298172,0.5785786815))
> res=metagen(yi,vi,sm="HR",data=unselectedother)
> forest(res)
### The efficacy of EGFR-TKIs among patients harboring EGFR mutation
> EGFR = data.frame(
+ yi=c(-0.5108256238,-1.203972804,-1.832581464,-1.272965676,-0.9942522733,-0.7153927895),
+ vi=c(0.3536465207,0.1582423104, 0.23979777, 0.1716695085,0.2000214734,0.19145476))
> res=metagen(yi,vi,sm="HR",data=EGFR)
> forest(res)
> funnel(res)
> metabias(res,method="linreg",k.min=5,plotit=TRUE)
### EGFR+ Past Smoker
> EGFRpastsmoker=data.frame(
+ yi=c(0.0487901642,-0.9416085399),
+ vi=c(0.4923882123,0.8763528046))
> res=metagen(yi,vi,sm="HR",data=EGFRpastsmoker)
> forest(res)
### EGFR+ Current Smoker
> EGFRcurrentsmoker=data.frame(
+ yi=c(-0.5798184953,-0.7765287895),
+ vi=c(0.6720925968,0.3763259914))
> res=metagen(yi,vi,sm="HR",data=EGFRcurrentsmoker)
> forest(res)
### EGFR+ Non Smoker
> EGFRnonsmoker=data.frame(
+ yi=c(-0.7635696449,-1.427116356,-1.427116356,-1.966112856),
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+ vi=c(0.2298232119,0.2397977,0.2068699531,0.2855182592))
> res=metagen(yi,vi,sm="HR",data=EGFRnonsmoker)
> forest(res)
### EGFR+ Male
> EGFRmale=data.frame(
+ yi=c(-0.398986142,-0.9675840263,-1.021651248,-1.347073648),
+ vi=c(0.3513705136,0.4103942937,0.2749982147,0.3158363308))
> res=metagen(yi,vi,sm="HR",data=EGFRmale)
>forest(res)
### EGFR+ Female
> EGFRfemale=data.frame(
+ yi=c(-0.7339691751,-1.049822124,-1.427116356,-2.040220829),
+ vi=c(0.2286901909,0.2368906164,0.268699531,0.3158363308))
> res=metagen(yi,vi,sm="HR",data=EGFRfemale)
> forest(res)
>
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